

In re Application of:

Frank McKeon et al.

Application No.: 09/538,106

Filed: March 29, 2000

For: Cell Regulatory Genes, Encoded Products, and Uses Related Thereto

Examiner: Yaen, Christopher H.

Art Unit: 1642

Attorney Docket No.: HMV-038.02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on September 15, 2004.

Shirine Darvish

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 (c)(3)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 23313-1450

Sir:

Listed on the enclosed Form PTO-1449 is a list of publications known to Applicants and their Attorney/Agent in compliance with the requirements of 37 C.F.R. 1.56. Copies of said publications are being submitted herewith. This submission follows the events recited in 37 C.F.R. § 1.97(c)(2); therefore, pursuant to 37 C.F.R. § 1.17 (p), please charge our Deposit Account No. 06-1448, Reference HMV-038.02 for the \$180.00 fee required under 37 C.F.R. § 1.97(c)(2). A duplicate copy of this submission is enclosed. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

09/17/2004 EAREGAY1 00000028 061448 09538106

01 FC:1806

180.00 DA

FHBoston/1100805.1

Atty Docket No. HMV-038.02

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies the cited documents as prior art against any claim in the application and Applicants determine that the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced publications be applied against the claims of the present application. If there is any additional fee due in connection with the filing of this Statement, the Director is hereby authorized to charge the fee to our Deposit Account, **No. 06-1448**, **Reference HMV-038.02**.

-2-

Date: September 15, 2004

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)

Respectfully Submitted,

Jennifer K. Holme Reg. No. 46,778

Attorney for Applicant

INFORMATION DISCLOSUBE (FIRETION IN AN APPLICATION (Use several sheets if necessary)				Docket Number (Optional) Application Number HMV-038.02 09/538,106 Applicant					
				McKeon et al. Filing Date Group Art Unit					
SEP 1 7 2004				March 29, 2000 1642					
EXAMINER INITIAL	T	OCUMENT NUMBER	DATE.	U.S. PATENT DOCU	CLA		SUBCLASS	FILING D	
INITIAL		TOTAL	DATE	NAME	CLA		SOBCEASS	IF APPROP	
•	-								
	<u>l .</u>		F	OREIGN PATENT DO	CUMENTS				
			DATE			ss	SUBCLASS Translation		
				3				YES	NO
									-
								,	
				CUMENTS			; Title, Date, Pert		1 c.)
	BV	Baylin et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene," Nature Genetics, 17:141-142 (1997)							
	BW	Beaudry et al., "Therapeutic targeting of the p53 tumor suppressor gene," Pharmaceutical Biotechnology, 592-600							
	вх	Cviko et al., "Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates," Hum Pathol., 31(6):740-744 (2000)							
		Damiani et al., "Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast,"							
	BY	Virchows Arch, 434:27-234 (1999)							
		De Laurenzi et al., "Evolution of Functions within the p53/p63/p73 Family," Ann N Y Acad Sci., 926:90-100 (2000)							
	BZ								
	CA	Foschini et al., "Carcinomas of the breast showing myoepithelial cell differentiation," Virchows Arch, 432:303-310 (1998)							
	СВ	Friedman et al., "The p53 protein is an unusually shaped tetramer that binds directly to DNA," Proc. Natl. Acad. Sci., 90:3319-3323 (1993)							
EXAMINER		<u> </u>			DATE CONSIDERED				
				not citation is in conformance		w line t	through citation	if not in	-
conformance and not considered. Include copy of this form with next communication to the applicant.									

Sheet Page 2 of 4

INFORMATION DISCHOSURE CITATION			Docket Number (Optional)		Application Number	
			HMV-038.02 Applicant		09/538,106	
(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)			McKeon et al.			
		SEP 1 7 2004	Filing Date		Group Art Unit	
		<u> </u>	March 29, 2000		1642	
		OTHER DO			g Author, Title, Date, Pertinent Pages Etc.)	
	СС				coprotein of human papillomavirus	
•	CD	Huibregtse et al., "Cloning and Expression of the cDNA for E6-AP, a Protein that Mediates the Interaction of the Human Papillomavirus E6 Oncoprotein with p53," Molecular and Cellular Biology, 13(2):775-784 (1993)				
	CE	Ince et al., "p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female Urogenital Tract," Am Journal of Pathol., 161(4):1111-1117 (2002)				
	CF	Lazar et al., "Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Molecular and Cellular Biology, 8(3):1247-1252 (1988)				
	CG	Le Bras et al., "Monoclonal antibodies raised against Xenopus p53 interact with human p73," Oncogene, 21:1304-1308 (2002)				
	СН	Levero et al., "The p53/p63/p73 family of transcription factors: overlapping and distinct functions," J Cell Sci. 113:1661-1670 (2000)				
	CI	40(=) 40= 400 (4000)	nd function of the p53-related	l proteins: same family	y, different rules," Trends Cell Biol.,	
	CJ	Mills et al., "p63 is a p53 hon	nologue required for limb an	d epidermal morphoge	enesis," Nature, 398:708-713 (1999)	
	СК	Nayar et al., "Immunoreactivity of ductal cells with putative myoepithelial markers: a potential pitfall in breast carcinoma," Ann Diagn Pathol., 3:165-173 (1999)				
	CL	O'Connell et al., "Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium: A Study with the p53 Homologue p63," Gynecol Oncol., 80(1):30-36 (2001)				
	СМ	Osada et al., "Cloning and functional analysis of human p51, which structurally and functionally resembles p53," Nat Med., 4(7):839-843 (1998)				
	CN	Quade et al., "Expression of the p53 Homologue p63 in Early Cervical Neoplasia," Gynecol Oncol, 80(1):24-29 (2001)				
	со	Ramnani et al., "Basal Cell-Specific Anti-Keratin Antibody 34βΕ12: Optimizing Its Use in Distinguishing Benign Prostate and Cancer," Mod. Pathology, 12:443-444 (1999)				
	СР	Sakamoto et al., "Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution," Proc. Natl. Acad. Sci., 9:8974-8978 (1994)				
	CQ	Scheffner et al., "Interaction of the Human Papillomavirus Type 16 E6 Oncoprotein with Wild-Type and Mutant Human p53 Proteins," Journal of Virology, 66(8):5100-5105 (1992)				
EXAMINER				DATE CONSIDERED		
		al if citation considered, whether of considered. Include copy of this			w line through citation if not in	

				Sheet Page 3 of 4			
orm PTO-1449		(O.E.)	Docket Number (Optional)	Application Number			
INFORMA	TION N. A.N	N DISCLOSPRECTATION N APPLICATION	HMV-038.02 Applicant	09/538,106			
(Us	se seve	eral sheet if necessary)	McKeon et al.				
·		SEP 1 7 2004	Filing Date	Group Art Unit			
			March 29, 2000	1642			
		OTHER 900		(Including Author, Title, Date, Pertinent Pages Etc.)			
	CR	Scheffnet et al., "The PV-16E6 and E6-AP Complex Functions as a Ubiquitin-Protein Ligase in the Ubiquitination of p53," Cell, 75.495-505 (1993)					
•	cs	Schweizer et al., "A reversibly palmitoylated resident protein (p63) of an ER-Golgi intermediate compartment is related to a circulatory shock resuscitation protein," Journal of Cell Science, 4:685-694 (1993)					
	СТ	Senoo et al., "A Second p53-Related Protein, p73L, with High Homology to p73," Biochem Biophys Res Commun., 248(3):603-607 (1998)					
	CU	Signoretti et al., "Basal Cell Specific p63 is Useful in the Differential Diagnosis of benign vs. Malignant Lesions of the Prostate," Presentation at the United States and Canadian Academy of Pathology (USCAP), March 29, 2000					
	CV	Signoretti et al., "p63 Is a Prostate Basal Cell Marker and is Required for Prostate Development," Am Journal of Pathol., 157(6):1769-1775 (2000)					
	cw	Sternlicht et al., "The Human Myoepithelial Cell Is a Natural Tumor Suppressor," Clin Cancer Research, 3:1949-1958 (1997)					
	сх	Theis et al., "A function in apoptosis other than transactivation inherent in the NH ₂ -terminal domain of p53," International Journal of Cancer, 71:858-866 (1997)					
	CY	Totten et al., "Microscopic Differential Diagnosis of Latent Carcinoma of Prostate," Arch Pathol., 55:131-141 (1953)					
	cz	Trink et al., "A new human p53 homologue," Nat. Med. 4(7):747-748 (1998)					
	DA	Urist et al., "Loss of p63 Expression is Associated with Tumor Progression in Bladder Cancer," Am Journal of Pathol., 161(4):1199-1206 (2002)					
	DB	Varma et al., "Discriminant staining patterns of small glandular and preneoplastic lesions of the prostate using high molecular weight cytokeratin (HMCK) - A study of 301 consecutive needle biopsies," Abstract, Mod Pathol., 1997, 10:93A					
	DC	Varma et al., "Effect of Formalin Fixation and Epitope Retrieval Techniques on Antibody 34βE12 Immunostaining of Prostatic Tissues," Mod Pathol., 12:472 (1999)					
	DD	Wang et al., "Histologic and Immunophenotypic Classification of Cervical Carcinomas by Expression of the p53 Homologue p63: A Study of 250 Cases," Hum Pathol., 32(5):479-486 (2001)					
	DE	Yang et al., "Lineage-specific expression of the P53 homologue P63 in genital tract neoplasia," Abstract, Mod Pathol., January 1999, 127A					
	DF	Yang et al., "P63: a P53 homologue that is a differentiation-specific marker in cervical squamous epithelium," Abstract, Mod Pathol., January 1999, 178A					
FXAMINER				ATE CONSIDERED			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION Sheet Page 4 of 4 Form PTO-1449 Docket Number (Optional) Application Number HMV-038.02 09/538,106 Applicant (Use several sheets if necessary)
SEP 1 7 2004 McKeon et al. Filing Date Group Art Unit March 29, 2000 1642 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.) Yang et al., Rare Expression of High-Molecular-Weight Cytokeratin in Adenocarcinoma of the Prostate Gland," Am J Surg Pathol., 23(2):147-152 (1999) DG Zeng et al., "NBP is the p53 homolog p63," Carcinogenesis, 22(2):215-219 (2001) DH EXAMINER DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.